Brian Cathers
Keine laufenden Positionen mehr
Profil
Brian Cathers worked as an Executive Director-Protein Homeostasis at Celgene Corp.
from 2015 to 2019.
He also worked as a Chief Scientific Officer at Global Blood Therapeutics, Inc. Dr. Cathers completed his undergraduate degree at Emporia State University and his graduate and doctorate degrees at the University of Kansas.
Ehemalige bekannte Positionen von Brian Cathers
Unternehmen | Position | Ende |
---|---|---|
CELGENE | Corporate Officer/Principal | 01.02.2019 |
GLOBAL BLOOD THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Ausbildung von Brian Cathers
Emporia State University | Undergraduate Degree |
University of Kansas | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 2 |
---|---|
Celgene Corp.
Celgene Corp. BiotechnologyHealth Technology Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ. | Health Technology |
Global Blood Therapeutics, Inc.
Global Blood Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Global Blood Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovering, developing and commercializing novel therapeutics to treat grievous blood-based disorders. It also provides oral medicines for sickle cell diseases. The company was founded by Matthew P. Jacobson, Andrej Sali, Jack Taunton, Charles J. Homcy, Craig D. Muir, and David R. Phillips in February 2011 and is headquartered in South San Francisco, CA. | Health Technology |